Taken together, our results support a model whereby NRAS and EZH2 mutations activate Gem expression through differential effects on gene transcription and cell differentiation, respectively, and distinct oncogenic mutations may act cooperatively to deregulate gene expression programs in leukemia-initiating cells. The gene discussed is NRAS; the disease is leukemia.